Provista Ramping Up Commercialization Efforts for Proteomic Videssa Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Provista Diagnostics is ramping up commercialization efforts for its Videssa Breast proteomic breast cancer test, expanding test availability from its initial clinical study partners to a somewhat larger group of early adopters, David Reese, Provista's president and CEO, told GenomeWeb this week.

The firm also is preparing to launch clinical utility and health economic studies to help drive payor coverage and clinical adoption of the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.